| 异基因造血干细胞移植治疗进展期慢性髓系白血病疗效及预后的初步分析 |
| |
| 引用本文： | 宋阿霞,杨栋林,魏嘉鳞,闫嶂松,王玫,姜尔烈,黄勇,马巧玲,何袆,翟卫华,张荣莉,冯四洲,韩明哲.异基因造血干细胞移植治疗进展期慢性髓系白血病疗效及预后的初步分析[J].中国实验血液学杂志,2011,19(1):149-153. |
| |
| 作者姓名： | 宋阿霞 杨栋林 魏嘉鳞 闫嶂松 王玫 姜尔烈 黄勇 马巧玲 何袆 翟卫华 张荣莉 冯四洲 韩明哲 |
| |
| 作者单位： | 1. 中国医学科学院、北京协和医学院血液学研究所、血液病医院,天津,300020;山东大学附属省立医院肿瘤微创综合治疗科,山东济南,250021
2. 中国医学科学院、北京协和医学院血液学研究所、血液病医院,天津,300020 |
| |
| 摘 要： | 加速期和急变期慢性髓系白血病(CML)患者预后较差,异基因造血干细胞移植(allo-HSCT)是这一类患者唯一具有治愈可能的治疗方法。本研究探讨allo-HSCT治疗进展期CML的疗效及预后。对1998年9月至2008年1月28例接受allo-HSCT的患者从疗效、移植前基础特点与预后、移植前治疗策略与预后、移植后事件与预后等方面进行了回顾性分析。结果表明:28例患者中10例活存并持续缓解,3年总活存率和无病活存率分别34.9%和35.7%;18例死亡。单因素分析发现,克隆演进和原始细胞比例是预后不良的基线危险因素,二者结合可以预测预后。移植前应用伊马替尼并取得完全血液学缓解并不能改善预后。对移植后事件的预后分析发现,并发重度移植物抗宿主病是预后不良的危险因素。结论:对于接受allo-HSCT治疗的进展期CML病例,克隆演进和原始细胞比例是具有预后意义,移植前应用伊马替尼并不能改善预后。
|
| 关 键 词： | 造血干细胞移植 慢性髓系白血病 加速期慢性髓系白血病 急变期慢性髓系白血病 伊马替尼 |
Preliminary Analysis of Therapeutic Efficacy and Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Advanced Chronic Myeloid Leukemia |
| |
| SONG A-Xia,YANG Dong-Lin,WEI Jia-Lin,YAN Zhang-Song,WANG Mei,JIANG Er-Lie,HUANG Yong,MA Qiao-Ling,HE Yi,ZHAI Wei-Hua,ZHANG Rong-Li,FENG Si-Zhou,HAN Ming-Zhe.Preliminary Analysis of Therapeutic Efficacy and Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Advanced Chronic Myeloid Leukemia[J].Journal of Experimental Hematology,2011,19(1):149-153. |
| |
| Authors: | SONG A-Xia YANG Dong-Lin WEI Jia-Lin YAN Zhang-Song WANG Mei JIANG Er-Lie HUANG Yong MA Qiao-Ling HE Yi ZHAI Wei-Hua ZHANG Rong-Li FENG Si-Zhou HAN Ming-Zhe |
| |
| Institution: | SONG A-Xia1,2,YANG Dong-Lin1,WEI Jia-Lin1,YAN Zhang-Song1,WANG Mei1,JIANG Er-Lie1,HUANG Yong1,MA Qiao-Ling1,HE Yi1,ZHAI Wei-Hua1,ZHANG Rong-Li1,FENG Si-Zhou1,HAN Ming-Zhe11Blood Disease Hospital and Institute of Hematology,Chinese Academy of Medical Sciences and Peking Union Medical College,Tianjin 300020,China,2Department of Oncology,Provincial Hospital Affiliated to Shandong University,Jinan 250021,Shandong Province |
| |
| Abstract: | Chronic myeloid leukemia(CML) at advanced and blastic phase is a disease with poor prognosis,for which allogeneic hematopoietic stem cell transplantation(allo-HSCT) is the only treatment choice with curative potential.This study was purposed to investigate the therapeutic efficacy of allo-HSCT and prognosis of advanced CML patients.The 28 cases of CML in accelerated phase or blast crisis received allo-HSCT were analysed retrospectively in terms curative efficacy,basic characteristics before transplant and p... |
| |
| Keywords: | hematopoietic stem cell transplantation chronic myeloid leukemia accelerated phase CML blast crisis CML imatinib |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
